soluble guanylate cyclase sgc stimulators class drugs developed treat heart failure pulmonary hypertension diseases firstinclass medication riociguat approved pulmonary also investigated hypertension systemic sclerosis sickle cell role nitric oxide cardiovascular disease received nobel prize physiology although still used treat angina side effects potential tolerance short duration action narrow therapeutic index limit therapeutic inhibitors increase approved erectile dysfunction pulmonary arterial hypertension pah benign prostatic hyperplasia less effective patients production suppressed people diabetes obesity soluble guanylate cyclase one downstream targets stimulators operate independently sgc activators another experimental class drugs may effective stimulators oxidative stress drugs also considered possibly potential treat kidney disease lung fibrosis scleroderma sickle cell httpsenwikipediaorgwikisolubleguanylatecyclasestimulator